JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary ...
Pulmonology Advisor

Review Highlights the Role of ncRNAs in IPF Pathogenesis

Regulatory mechanisms mediated by non-coding RNAs provide valuable insights into the pathogenesis of idiopathic pulmonary fibrosis.

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive ...
Pharmaceutical Technology on MSN

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

The approval is based on Phase III FIBRONEER-IPF and FIBRONEER-ILD clinical trials conducted in parallel.
Kaleido Scope

Learn More About IPF

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
The American Journal of Managed Care

Patients With IPF Face QOL Challenges With Antifibrotic Treatment

Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...
Pulmonology Advisor

Study Finds No Link Between PCSK6 and Worse Respiratory Outcomes in Mixed Fibrotic ILD

The levels of PCSK6 are not associated with worse respiratory outcomes in patients with mixed fibrotic interstitial lung disease.